	FORM	14	U	NITE	ED S	ΓΑΤ	ES				ND EXC 0.C. 20549	HAN	GE C	OWN	AISSION	l		OMP	APPR		
Check this box if no longer subject to				STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP														3235-0287			
Section 16. Form 4 or Form 5 obligations				Filed	ed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										s per resp	-	0.5				
transa contra purch issue affirm	ase or sale of eo r that is intended ative defense co	pursuant to a r written plan for the quity securities of the to satisfy the anditions of Rule						,													
10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person [*] <u>TPG GP A, LLC</u>					2. Issuer Name and Ticker or Trading Symbol Bicara Therapeutics Inc. [BCAX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner									
C/O TPG INC.			·	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 09/16/2024							Officer (give title I Other (specify below) Former 10% Owner							
301 COMMERCE STREET, SUITE 3300 (Street) FORT WORTH TX 76102				4. If Am			endment, Date of Original Filed (Month/Day/Year)							 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person 							
(City)		(State)	(Zip)			,									F	orm file	a dy ivior	e than O	пе керо	rting Person	
			Table	I - No	on-De	rivat	ive S	Securitie	s Acq	uirec	d, Dispose	d of, d	or Bei	neficia	ally Owne	d					
1. Title of	Security (Ins	tr. 3)		2. Transaction Date (Month/Day/Yea			if any	emed tion Date, n/Day/Year)	3. Transa Code (I 8)			s Acquired (A) or)f (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially (Following	Owned (D) or (I) (Inst		Direct B ndirect (I		e of Indirect ial Ownership		
									Code	v	Amount	(A) c (D)	Pri Pri	ice	Reported Transaction(s) (Instr. 3 and 4)						
Common Stock 09/16/2024				4			С		1,960,42	5 A		(3)	1,960,425		Ι			xplanation of nses ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾			
			Та	ble II							Disposed ons, conv										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any			nsaction Der de (Instr. Sec Acc Dis		umber of ivative urities uired (A) or posed of (D) tr. 3, 4 and	6. Date Exerce Expiration Da (Month/Day/)		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	tive ties cially d ring ted	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	ship Ber Ow D) ect	Nature of Indireo neficial mership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title		ount or nber of ires	Transact (Instr. 4)						
Series C Preferred Stock	(3)	09/16/2024			с			18,121,194	. (3)	(3)	Commo Stock		60,425	(3)		0	I	See Res	e Explanation of sponses ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽	
	and Address of <u>GP A, LLC</u>	Reporting Person*	*			·			,		-										
(Last) (First) C/O TPG INC.				(Middle)																	
301 CO	MMERCE S	STREET, SUITE	3300																		
(Street) FORT WORTH TX 76102																					
(City)		(State)	(Zip)																	
	and Address of DERMAN	Reporting Person*	• 																		
(Last) (First) (Middle) C/O TPG INC.																					
		STREET, SUITE	E 3300																		
(Street) FORT WORTH TX 76102																					
(City) (State) (Zip)																					
	and Address of TER JAN	Reporting Person [*]																			
(Last) (First) (Middle) C/O TPG INC. 301 COMMERCE STREET, SUITE 3300																					
(Street)		, 50111																			

(Street)		
FORT WORTH	TX	76102

SEC Form 4

(City)	(State)	(Zip)						
1. Name and Address of Reporting Person* WINKELRIED JON								
(Last) C/O TPG INC. 301 COMMERCE S	(First) IREET, SUITE 3300	(Middle)						
(Street) FORT WORTH	ТХ	76102						
(City)	(State)	(Zip)						

Explanation of Responses:

1. Each of David Bonderman, James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Bonderman, Coulter and Winkelried, the "Reporting Persons"), which is the general partner of TPG Group Holdings (BSS), L.P., and (ii) Alabama Investments (Parallel), GP, LLC, which is the general partner of each of (a) Alabama Investments (Parallel), DR, by Alabama Investments (Pa

2. TPG Inc. is the sole member of TPG GPC0, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG LSI GenPar Advisors, LLC, which is the general partner of TPG LSI GenPar, L.P., which is the sole member of TPG USI SPV GP, LLC, which is the general partner of TPG LSI Rise Butterfly, L.P. ("TPG Butterfly I"), which directly holds 1,960,425 shares of Common Stock ("Common Stock") of Bicara Therapeutics Inc. (the "Issuer").

3. Pursuant to the Fourth Amended and Restated Certificate of Incorporation of the Issuer, the 18,121,194 shares of Series C Preferred Stock of the Issuer held by TPG Butterfly I automatically converted into 1,960,425 shares of Common Stock upon consummation of the Issuer's initial public offering on September 16, 2024. The shares of Series C Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at a conversion rate (reflecting the 1-for-9.2435 reverse stock split effected on September 5, 2024) equal to one share of Common Stock per 9.2435 shares of Series C Preferred Stock, subject to adjustment.

4. Because of the relationship between the Reporting Persons and TPG Butterfly I, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Butterfly I and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Butterfly I's or such Reporting Person's pecuniary interest therein, if any.

5. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Remarks:

(6) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. (7) Gerald Neugebauer is signing on behalf of Messrs. Bonderman, Coulter and Winkelried pursuant to authorization and designation letters dated January 10, 2024, which were previously filed with the Securities and Exchange Commission.

/s/ Bradford Berenson, General Counsel, TPG GP A, LLC (6)	<u>09/18/2024</u>
/s/ Gerald Neugebauer, on behalf of David Bonderman (6) (7)	<u>09/18/2024</u>
/s/ Gerald Neugebauer, on behalf of James G. Coulter (6) (7)	<u>09/18/2024</u>
/s/ Gerald Neugebauer, on behalf of Jon Winkelried (6) (7)	<u>09/18/2024</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.